Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics, Inc. (CADL) – Form 4 filing dated 06/24/2025
The company’s Chief Financial Officer, Charles Schoch, reported the grant of a stock option for 50,000 shares of common stock with an exercise price of $4.75 per share. The option was issued on 06/20/2025 and will expire on 06/20/2035.
Vesting schedule: 25 % of the award vests on 06/20/2026; the remaining 75 % vests in 36 equal monthly installments thereafter, contingent on continued service.
Following this transaction, Mr. Schoch beneficially owns 50,000 derivative securities (stock options) directly. No open-market purchases or sales of CADL common shares were disclosed.
Candel Therapeutics has announced a registered direct offering of 3,221,395 shares of common stock at $4.67 per share, expected to raise approximately $15.0 million in gross proceeds. The offering price equals the closing price reported on Nasdaq Global Market on June 23, 2025.
Key details of the offering include:
- Purchasers include existing healthcare-focused institutional investors, executive officers, and directors
- Offering is made under shelf registration statement (File No. 333-266605) declared effective August 12, 2022
- Closing anticipated for June 25, 2025, subject to customary conditions
The company, an emerging growth company, is conducting this offering to strengthen its financial position. The securities purchase agreement was signed on June 23, 2025, with shares being offered through a registered direct offering structure. This strategic financing move involves both institutional and insider participation, potentially signaling management's confidence in the company's prospects.